Scinovex
article Open AccessTop 1% cited

Clinical trial: the effects of a trans‐galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome

Alimentary Pharmacology & Therapeutics · 2008 · Vol. 29(5) · pp. 508–518
D. B. A. SilkAndrew M. DavisJelena VulevicGeorge TzortzisGlenn R. Gibson

Abstract

The galactooligosaccharide acted as a prebiotic in specifically stimulating gut bifidobacteria in IBS patients and is effective in alleviating symptoms. These findings suggest that the prebiotic has potential as a therapeutic agent in IBS.

Gastrointestinal motility and disordersGut microbiota and healthInfant Health and DevelopmentPrebioticIrritable bowel syndromeMedicineFlatulenceGastroenterologyBloatingInternal medicinePlaceboCrossover studyRandomized controlled trial

MeSH terms

AdultAgedBifidobacteriumFecesFemaleHumansMaleMiddle AgedOligosaccharidesQuality of LifeStatistics as TopicColony Count, MicrobialTreatment OutcomeProbioticsIrritable Bowel Syndrome
Citations
538
FWCI
12.63
field-weighted impact
References
48
Percentile
99%
vs. same field & year
Citations per year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.